| Followers | 39 |
| Posts | 2870 |
| Boards Moderated | 0 |
| Alias Born | 12/06/2003 |
Friday, December 15, 2017 5:12:58 PM
Aratana Therapeutics Announces Study Results for AT-016
On December 14, 2017, Aratana's license partner responsible for the development of AT-016 shared the results of a pivotal study, which did not achieve protocol-defined efficacy success criteria. As part of Aratana's exclusive commercial license for dogs with osteoarthritis in the United States, Aratana had funded the clinical study and other work. Aratana anticipates that after its license partner has further evaluated the study results, the parties will determine if the collaboration to bring the therapeutic to market will continue.
https://tinyurl.com/yagmm4p4
I was a bit - just a bit - surprised since Mike West's agglomeration of companies are working miracles - wouldn't curing the blind qualify? - but many others are stumbling.
I guess the lesson is if you want something done do it yourself?
Don't confuse that with Galliprant. Galliprant is also a true wonder drug from our own experience with our dog's osteoarthritis.
Best, Terry
On December 14, 2017, Aratana's license partner responsible for the development of AT-016 shared the results of a pivotal study, which did not achieve protocol-defined efficacy success criteria. As part of Aratana's exclusive commercial license for dogs with osteoarthritis in the United States, Aratana had funded the clinical study and other work. Aratana anticipates that after its license partner has further evaluated the study results, the parties will determine if the collaboration to bring the therapeutic to market will continue.
https://tinyurl.com/yagmm4p4
I was a bit - just a bit - surprised since Mike West's agglomeration of companies are working miracles - wouldn't curing the blind qualify? - but many others are stumbling.
I guess the lesson is if you want something done do it yourself?
Don't confuse that with Galliprant. Galliprant is also a true wonder drug from our own experience with our dog's osteoarthritis.
Best, Terry
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
